- Amarin is a pharmaceutical company offering products to improve cardiovascular health.
- The company’s clinical results are quite successful. We are talking about 20% reduction in cardiovascular deaths.
- The company expects to launch products in approximately 20 additional markets from 2022 to 2024. The company believes that international growth could represent close to $1 billion in potential revenue.
- I believe that the revenue will grow significantly in the coming years because the company is hiring new sales professionals. In 2018, sales personnel were equal to 170. In 2020, the number of sales personnel increased to close to 900.
- I also expect that AMRN will be able to sell products in Mainland China and Hong Kong. Notice that the company expects to receive a lot of information from authorities in China by the end of 2021.
For further details see:
Amarin Stock: Sales From China And Europe May Make The Price Spike Up